Please ensure Javascript is enabled for purposes of website accessibility

Why Spectrum Pharmaceuticals Stock Jumped Higher Today

By George Budwell - Oct 18, 2017 at 4:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Spectrum's stock got a huge lift from its mid-stage lung cancer drug candidate today.

What happened

Spectrum Pharmaceuticals (SPPI -2.86%), a biotech developing treatments for various blood disorders and cancers, saw its shares gain as much as 51.7% today on over 19 times the average volume. The spark was provided by an extremely impressive interim data release for the company's non-small cell lung cancer (NSCLC) candidate, poziotinib. Poziotinib's interim mid-stage results were released as part of an oral presentation at the 18th World Conference on Lung Cancer in Yokohama, Japan.

A rocket taking flight

Image source: Getty Images.

So what

Spectrum has long been an oddball in commercial-stage oncology, because the company has largely failed to generate a robust revenue stream on a consistent basis -- despite having multiple products on the market. The crux of the problem is that Spectrum's diverse product portfolio lacks a bona fide star to drive growth.

Poziotinib, however, appears capable of filling that critical gap in the company's lineup. After all, 11 evaluable patients in this mid-stage study showed at least some amount of tumor shrinkage. The drug's safety profile also appears to be fairly standard for a tyrosine-kinase inhibitor, meaning that safety issues shouldn't be a major concern.

Now what

Of course, it is important to bear in mind that these results -- while impressive -- are based on an exceedingly small sample of NSCLC patients. In other words, Spectrum probably won't be able to apply for an accelerated approval pathway with either American or European regulatory authorities.

Investors should therefore probably brace themselves for a fairly large secondary offering, within the next few trading sessions, as a way to fund the drug's clinical development. Spectrum, after all, exited the most recent quarter with only $138.5 million in its coffers.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Spectrum Pharmaceuticals, Inc. Stock Quote
Spectrum Pharmaceuticals, Inc.
$0.78 (-2.86%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.